Beone Medicines Ltd. revenue by segment BEIGF

Annual Quarterly

Beone Medicines Ltd. splits its revenue into 10 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was BRUKINSA at $1.4 billion, 74% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	6,606	1,890	1,705	1,513	1,498	1,412	1,315	1,117	1,128
Product	—	—	—	1,487 +34.2% share 98.3%	1,476 +32.1% share 98.5%	—	—	1,109 share 99.2%	1,118 share 99.1%
BRUKINSA	—	1,391 +33.7% share 73.6%	1,248 +31.4% share 73.2%	—	—	1,041 share 73.7%	950 share 72.2%	—	—
TEVIMBRA	—	243 +27.6% share 12.9%	229 +18.1% share 13.4%	—	—	191 share 13.5%	194 share 14.7%	—	—
XGEVA	—	—	104 +28.5% share 6.1%	—	—	84 share 6.0%	81 share 6.2%	—	—
BLINCYTO	—	39 share 2.1%	37 +42.8% share 2.1%	—	—	—	26 share 1.9%	—	—
Other Revenue	—	35 +101.3% share 1.8%	—	26 +198.4% share 1.7%	22 +122.0% share 1.5%	17 share 1.2%	13 share 1.0%	9 share 0.8%	10 share 0.9%
Other	—	30 +235.6% share 1.6%	38 +78.8% share 2.2%	—	—	9 share 0.6%	21 share 1.6%	—	—
BAITUOWEI	—	22 +96.7% share 1.2%	—	—	—	11 share 0.8%	—	—	—
KYPROLIS	—	14 share 0.7%	15 -22.0% share 0.9%	—	—	—	19 share 1.5%	—	—
POBEVCY	—	11 +2.1% share 0.6%	10 -14.3% share 0.6%	—	—	10 share 0.7%	11 share 0.9%	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ONC (Nasdaq), BEIGF (OTC)
Fiscal year ends: December 31
Headquarters: Basel
SEC filer status: Large accelerated filer
SEC CIK: 1651308
Former names: BeiGene, Ltd. (until May 27, 2025)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.